Abstract: Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion. The robustness of these clonally-purified lines, their ability to expand for >40 passages while maintaining their pattern of gene expression, lack of tumorigenicity, and their embryonic pattern of gene expression offers novel compositions and methods for modeling numerous differentiation pathways for the first time in vitro, and for the manufacture of purified product not existing in such a purified state in nature or using other manufacturing modalities. Representative progenitor cell lines described herein are capable of development into cutaneous adipocytes, blood-brain barrier cells, neuronal cells, or smooth muscle cells each with therapeutic potential.
Type:
Grant
Filed:
December 18, 2017
Date of Patent:
February 16, 2021
Assignee:
LINEAGE CELL THERAPEUTICS, INC.
Inventors:
Michael West, Hal Sternberg, Karen Chapman
Abstract: Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.
Abstract: Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGF?/Activin/Nodal signaling and BMP signaling are provided. Also provided are methods and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.
Type:
Application
Filed:
September 19, 2019
Publication date:
March 19, 2020
Applicant:
Lineage Cell Therapeutics, Inc.
Inventors:
Rekha R. Nair, Stephanie Kayser, Abhirath S. Parikh, Uzma Shoukat-Mumtaz, Erik Michael Whiteley, Nathan C. Manley, Craig R. Halberstadt